Pharmacy & Therapeutics - November 2008 - (Page 666)

Switching from FDC to FC Antihypertensive Medications 1996;5(3):249–265. 32. Drummond M, Coyle D. Assessing the economic value of antihypertensive medicines. J Hum Hypertens 1992;6(6):495–501. 33. Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: Hypertension stage, type of drug, or therapeutic compliance? J Hypertens 2001;19(1):149–155. 34. Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989;27(12):1159–1166. 35. Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich) 2003;5(3 Suppl 2):3–13. 36. Cushman WC. The burden of uncontrolled hypertension: Morbidity and mortality associated with disease progression. J Clin Hypertens 2003;5(3):14–22. 37. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: The cardiovascular health study. Arch Intern Med 2001;161(9):1183–1192. 38. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Arch Intern Med 1996;156(16):1789–1796. 39. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903–1913. 40. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357(9268): 1601–1608. 41. Hebert LA, Kusek JW, Greene T et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997; 30(3 Part 1):428–435. 42. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70: 41–55. 43. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006; 9(6):377–385. 44. Manning WG, Mullahy J. Estimating log models: To transform or not to transform? J Health Econ 2001;20(4):461–494. 45. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 2004;23(3):525–542. 46. Soni A. The Five Most Costly Conditions, 2000 and 2004: Estimates for the Civilian Noninstitutional Population. Statistical Brief No. 167. Agency for Healthcare Research and Quality, 2007. 47. Machlin SR, Carper K. National Health Care Expenses in the U.S Civilian Noninstitutionalized Population, 2004. Statistical Brief No. 149. Agency for Healthcare Research and Quality, 2006. 48. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19(11):1190–1196. 49. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: A proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40(7–8):1280–1288. 50. Mattke S, Jain AK, Sloss EM, et al. Effect of disease management on prescription drug treatment: What is the right quality measure? Dis Manag 2007;10(2):91–100. 51. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10(1):3–12. 52. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008(11). Electronic version, June 25, 2007 (doi:10.1111/j.1524–4733. 2007.00213.x). Available at: www.ispor. org/sigs/medcompliance/ MedicationComplianceandPersistence.asp. 53. Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: The case of statin treatment. Am J Manag Care 2005; 11(11):670–674. I Try Our New Digital Edition The digital edition of P&T is now available. Readers see a complete copy of an issue on their computer screens, with the added ability to search through every single word in the issue. With the digital edition, you can: • click on any URL anywhere in the magazine and go directly to that Web page. • click on the title of any article on the cover or in the table of contents and go directly to that article. • search for any string of characters. • make and save notes with the article that you are reading. • instantly e-mail a link to any article to an associate. • get more information about advertised products by clicking on an ad. • save the magazine file to your desktop for offline reading. • print any or all pages. November 2008 www.PTCommunity.com Volume 33 Number 11 How to Use the Digital Edition To navigate through the issue, use the control bar at the top of the screen. Turn the pages as you would do with the print edition. To access more help click on the red question mark in the bar. Opens the Tools menu. View a list of all articles. Zoom in and out on the current page. Click the word “Zoom” to open the zoom configuration window. Switch to single-page view. Open the magnify window. Navigate to the previous or next page. Navigate to the cover or back page. Search the full text of the issue for a word or phrase. Print pages. Save an offline version to your computer. Save the direct link to an article to bookmark or email COVER STORY A Peer-Reviewed Jour nal for Managed Care and Hospital Formular y Management Heparin-Induced Thrombocytopenia Overview and Treatment D. A. Zinkovsky, PharmD, and M. S. Antonopoulos, PharmD, FASCP MEETING HIGHLIGHTS European Society for Medical Oncology Association for the Study of Bone And Mineral Research W. Alexander MEDICATION ERRORS DRUG FORECAST Ceftobiprole, a Broad-Spectrum Cephalosporin with Activity Against Methicillin-Resistant Staphylococcus aureus (MRSA) J. Kisgen, PharmD, and D. Whitney, PharmD, BCPS PRESCRIPTION: WASHINGTON DEA Opens the Door to e-Prescribing Of Controlled Substances But Pharmacies Balk at Security Rules S. Barlas You can receive P&T’s digital edition every month free by registering here: http://www.ptcommunity.com/digital Medication Utilization Patterns and Hypertension-Related Expenditures Among Patients Who Were Switched From Fixed-Dose To Free-Combination Antihypertensive Therapy G. Hess, MD, MBA; J. Hill, PhD; H. Lau, MS; H. Dastani, PhD; and P. Chaudhari, PharmD, MPH SIGN UP NOW to receive an alert when each new issue is available: http://www.ptcommunity.com/digital 666 P&T® • November 2008 • Vol. 33 No. 11 http://www.PTCommunity.com http://www.ptcommunity.com/digital http://www.ptcommunity.com/digital http://www.ispor.org/sigs/medcompliance/MedicationComplianceandPersistence.asp http://www.ispor.org/sigs/medcompliance/MedicationComplianceandPersistence.asp

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - November 2008

Pharmacy & Therapeutics - November 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/New Medical Devices Drug Forecast Heparin-Induced Thrombocytopenia Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched From Fixed-Dose to Free-Combination Antihypertensive Therapy European Society for Medical Oncology and Association for the Study of Bone and Mineral Research Pharmaceutical Approval Update

Pharmacy & Therapeutics - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.